全文获取类型
收费全文 | 1634篇 |
免费 | 46篇 |
国内免费 | 67篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 37篇 |
妇产科学 | 8篇 |
基础医学 | 189篇 |
口腔科学 | 11篇 |
临床医学 | 83篇 |
内科学 | 361篇 |
皮肤病学 | 9篇 |
神经病学 | 202篇 |
特种医学 | 100篇 |
外科学 | 132篇 |
综合类 | 237篇 |
预防医学 | 56篇 |
眼科学 | 6篇 |
药学 | 209篇 |
1篇 | |
中国医学 | 25篇 |
肿瘤学 | 77篇 |
出版年
2023年 | 5篇 |
2022年 | 13篇 |
2021年 | 30篇 |
2020年 | 27篇 |
2019年 | 23篇 |
2018年 | 23篇 |
2017年 | 23篇 |
2016年 | 27篇 |
2015年 | 28篇 |
2014年 | 88篇 |
2013年 | 71篇 |
2012年 | 55篇 |
2011年 | 75篇 |
2010年 | 58篇 |
2009年 | 74篇 |
2008年 | 110篇 |
2007年 | 76篇 |
2006年 | 81篇 |
2005年 | 73篇 |
2004年 | 67篇 |
2003年 | 53篇 |
2002年 | 49篇 |
2001年 | 32篇 |
2000年 | 49篇 |
1999年 | 45篇 |
1998年 | 44篇 |
1997年 | 48篇 |
1996年 | 30篇 |
1995年 | 35篇 |
1994年 | 37篇 |
1993年 | 29篇 |
1992年 | 23篇 |
1991年 | 21篇 |
1990年 | 30篇 |
1989年 | 26篇 |
1988年 | 25篇 |
1987年 | 24篇 |
1986年 | 20篇 |
1985年 | 14篇 |
1984年 | 13篇 |
1983年 | 5篇 |
1982年 | 12篇 |
1981年 | 17篇 |
1980年 | 6篇 |
1979年 | 13篇 |
1978年 | 7篇 |
1977年 | 4篇 |
1976年 | 6篇 |
1975年 | 1篇 |
1909年 | 1篇 |
排序方式: 共有1747条查询结果,搜索用时 31 毫秒
51.
Dario Giugliano Federico Cacciapuoti Mario Verza Giuseppe Rosato Michele Varricchio 《Acta diabetologica》1979,16(4):331-337
Summary The aim of the present study was to evaluate possible hemodynamic effects of somatostatin in insulin-dependent diabetic subjects.
For this purpose, 7 insulin-requiring juvenile-onset diabetics were submitted to a short-term infusion of cyclic somatostatin
(250 μg/h, over 2 h) or saline in randomized order. Somatostatin infusion resulted in a progressive and significant decrease
in heart rate, stroke volume, cardiac index and velocity circumferential fiber; on the other hand, left ventricular ejection
time was augmented by somatostatin. None of these effects was seen in the saline control study. We conclude that somatostatin
exerts a negative inotropic effect in insulin-dependent diabetes. 相似文献
52.
Basal and tolbutamide-induced plasma somatostatin in healthy subjects and in patients with diabetes and impaired glucose tolerance 总被引:1,自引:0,他引:1
Peripheral levels of basal and tolbutamide-induced somatostatin have been measured in patients with diabetes or impaired glucose tolerance (IGT) and compared with those in normal individuals. Basal somatostatin was significantly higher in patients with Type 1 diabetes than in age-matched control subjects. This increase was most pronounced at diagnosis, and appeared to be related to metabolic control in insulin-treated patients. No increase was noted in patients with Type 2 diabetes or with IGT. Intravenous bolus injection of tolbutamide enhanced peripheral somatostatin levels in healthy volunteers in a biphasic manner. Patients with IGT also exhibited a biphasic response but the amplitude of the first phase was higher. No secretory response was detected in 27/29 Type 1 diabetic patients at diagnosis; a somatostatin response to tolbutamide became detectable again in Type 1 patients with normalization of their basal somatostatin levels but was then paradoxically related to poor blood glucose control. In Type 2 diabetes, basal somatostatin levels were similar to age-matched control subjects, but decreased upon intravenous tolbutamide administration. 相似文献
53.
急性胰腺炎患者致炎与抗炎因子的变化及生长抑素的调节作用 总被引:12,自引:0,他引:12
目的:探讨急性胰腺炎患者血浆中致炎因子肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)和抗炎因子转化细胞生长因子-β(TGF-β)、白介素-10(IL-10)的变化、意义及生长抑素的调节作用。方法:急性胰腺炎48例,随机分成生长抑素治疗组和常规治疗组,分别在治疗前(入院时)、治疗后8 h和第2、3、4 d清晨空腹抽肘静脉血3 ml,测定TNF-α、IL-6、TGF-β和IL-10,并设对照组。结果:TNF-α和IL-6各监测点均比对照组显著升高(P<0.05,P<0.01),高峰在入院时。TGF-β和IL-10入院后8 h以后各监测点均比对照组显著升高(P<0.05,P<0.01);第2天达高峰。生长素抑素治疗组TNT-α、IL-6、和TGF-β、IL-10含量治疗后8 h明显低于常规治疗组。治疗后各观察点持续降低(P<0.05,P<0.01)。结论:急性胰腺炎患者血中致炎因子与抗炎因子均升高,机体免疫功能紊乱。生长抑素对致炎因子与抗炎因子的升高有抑制作用。 相似文献
54.
We present a case report of a patient with a suspicious ileal carcinoid tumour. Clinical examination as well as computer tomograghy (CT) scan suggested a tumour. Octeotride scan showed uptake in the same bowel loop reported as pathological in CT. The patient underwent surgery and biopsy which reported Crohn’s disease (CD). The interest in the case is due to the fact that this is, to the best of our knowledge, the second report of Crohn’sdisease as a cause of false positive octeotride scan. Unfortunately, no somatostatin recptors could be found in the sample, so further studies should be performed. 相似文献
55.
生长抑素受体介导靶向放疗是建立在对生长抑素、生长抑素类似物及其受体的研究基础之上.目前已经证实生长抑素类似物有良好的抗肿瘤效应,应用放射性核素标记生长抑素类似物与消化系统肿瘤高表达的生长抑素受体特异性和选择性结合以达到两者共同抗肿瘤作用的方法,具有重要的应用前景.本文就生长抑素受体介导的靶向放疗在消化系统肿瘤治疗方面的研究进展作一综述. 相似文献
56.
Summary A method for the determination of immunoreactive somatostatin in rat plasma is described. Blood specimens were collected into aprotinin and EDTA. Plasma was separated, immediately diluted with acidified acetone and ultrasonicated. The resultant supernatant was lyophilised. The dilution curve of the material thus extracted was parallel to that of synthetic somatostatin. The material was eluted mainly in a similar position to that of synthetic somatostatin on Sephadex G-25 (f) column chromatography. The somatostatin immunoreactivity was degraded significantly from the pre-incubated value of 846±86 pg/ml (n=4, mean±SEM) to 102±16 pg/ml in the same manner as that of synthetic somatostatin when incubated with one ml of fresh rat plasma at 37 °C for 30 min. The mean recovery in quadruplicate of immunoreactive somatostatin at concentrations of 100, 200 and 400 pg/ml was 83±7, 95±4 and 76±4%, respectively. Using this method, plasma immunoreactive somatostatin responses to arginine, glucose and glucagon infusion were measured in pentobarbital anaesthetized rats. The mean basal plasma immunoreactive somatostatin concentration in the jugular vein was 35±3 pg/ml (n=7), while that in the hepatic portal vein was 120±17 pg/ml (n=7). Infusion of arginine, glucose and glucagon all resulted in 2–3 fold increases in portal plasma immunoreactive somatostatin concentration. 相似文献
57.
The role of cortistatin in the human immune system 总被引:1,自引:0,他引:1
Cortistatin (CST) is a recently described neuropeptide that shares high homology with somatostatin (somatotropin release-inhibiting factor, SRIF) and binds with high affinity to all somatostatin (sst) receptor subtypes. CST is currently known to have a widespread distribution in many human organs including the immune system. The activities specific to CST may be partially attributable to its binding to the growth hormone secretagogue (GHS)-receptor (GHS-R) and the orphan G-protein-coupled receptor MrgX2. Human immune cells produce CST, whereas macrophage lineage and activated endothelium express sst2, and human lymphocytes express sst3. The human thymus expresses sst1, 2, 3, MrgX2 and almost all immune cells express GHS-R. Moreover, at this very moment promising research with CST in experimental animal models is being performed. On the basis of these promising results, studies aiming to further evaluate the possibilities of CST as a therapeutic agent in human immune-mediated inflammatory diseases are warranted. 相似文献
58.
59.
《Pancreatology》2020,20(2):158-168
BackgroundPost-operative pancreatic fistula (POPF) is a common complication of pancreatic resection. Somatostatin analogues (SA) have been used as prophylaxis to reduce its incidence. The aim of this study is to appraise the current literature on the effects of SA prophylaxis on the prevention of POPF following pancreatic resection.MethodsThe review of the literature was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data from studies that reported the effects of SA prophylaxis on POPF following pancreatic resection were extracted, to determine the effect of SA on POPF morbidity and mortality.ResultsA total of 15 studies, involving 2221 patients, were included. Meta-analysis revealed significant reductions in overall POPF (Odds ratio: 0.65 (95% CI 0.53–0.81, p < 0.01)), clinically significant POPF (Odds ratio: 0.53 (95% CI 0.34–0.83, p < 0.01)) and overall morbidity (OR: 0.69 (95% CI: 0.50–0.95, p = 0.02)) following SA prophylaxis. There is no evidence that SA prophylaxis reduces mortality (OR: 1.10 (95%CI: 0.68–1.79, p = 0.68)).ConclusionSA prophylaxis following pancreatic resection reduces the incidence of POPF. However, mortality is unaffected. 相似文献
60.
El-Salhy M Gilja OH Gundersen D Hausken T 《World journal of gastrointestinal endoscopy》2014,6(5):36-45
AIM: To study the different endocrine cell types in the oxyntic mucosa of patients with irritable bowel syndrome (IBS).METHODS: Seventy-six patients with IBS were included in the study (62 females and 14 males; mean age 32 years, range 18-55 years), of which 40 also fulfilled the Rome III criteria for functional dyspepsia (FDP). Of the entire IBS cohort, 26 had diarrhea as the predominant symptom (IBS-D), 21 had a mixture of diarrhea and constipation (IBS-M), and 29 had constipation as the predominant symptom (IBS-C). Forty-three age and sex-matched healthy volunteers without any gastrointestinal complaints served as controls. The patients were asked to complete the Birmingham IBS symptom questionnaire. Both the patients and controls underwent a standard gastroscopy, during which three biopsy samples were taken from the corpus. Sections from these biopsy samples were immunostained using the avidin-biotin complex (ABC) method, for ghrelin, serotonin, somatostatin and histamine. The densities of these cell types and immunoreactivity intensities were quantified using computerized image analysis with Olympus cellSens imaging software (version 1.7).RESULTS: The densities of the ghrelin cells in the control, IBS-total, IBS-D, IBS-M and IBS-C groups were 389 (320, 771), 359 (130, 966), 966 (529, 1154), 358 (120, 966) and 126 (0, 262) cells/mm2, respectively. There was a significant difference between the tested groups (P < 0.0001). Dunn’s multiple comparison test showed that the ghrelin cell density was significantly higher in IBS-D and lower in IBS-C than in the controls (P = 0.03 and 0.0008, respectively). The ghrelin cell density in patients with both IBS and FDP was 489 (130, 966), and in those with IBS only 490 (130, 956). There was no statistical significant difference between these 2 groups of patients (P = 0.9). The immunoreactivity intensity did not differ between any of the groups (P = 0.6). The diarrhea score of the Birmingham IBS symptom questionnaire was significantly positively correlated with ghrelin cell density (r = 0.65; P < 0.0001) and significantly inversely correlated with that of constipation (r = 90.69; P < 0.0001). The densities of the serotonin cells were 63 (51, 82), 51 (25, 115), 120 (69, 128), 74 (46, 123) and 40 (0, 46) cells/mm2 in the control, IBS-total, IBS-D, IBS-M and IBS-C groups, respectively. A statistically significant difference was found between the tested groups (P < 0.0001). Posttest revealed that serotonin cell density was significantly higher in IBS-D and lower in IBS-C than in controls (P = 0.02 and 0.004, respectively), but did not differ in the IBS-total and IBS-M groups from that in controls (P = 0.5 and 0.4, respectively). The serotonin cell density in patients with both IBS and FDP was 62 (25, 115) and in those with IBS only 65 (25, 123). There was no statistically significant difference between these 2 groups of patients (P = 1). The immunoreactivity intensity of serotonin did not differ significantly between any of the groups (P = 0.0.9). The serotonin cell density was significantly positively correlated with the diarrhea score of the Birmingham IBS symptom questionnaire (r = 0.56; P < 0.0001) and significantly inversely correlated with that of constipation (r = 0.51; P < 0.0001). The densities of the somatostatin cells were 97 (72, 126), 72 (0, 206), 29 (0, 80), 46 (0, 103) and 206 (194, 314) cells/mm2 in the control, IBS-total, IBS-D, IBS-M and IBS-C groups, respectively (Figures 7 and 8). There was a statistically significant difference between the controls and the IBS subgroups (P < 0.0001). The density of somatostatin cells was significantly lower in the IBS-D and IBS-M groups but higher in IBS-C patients than in the controls (P < 0.01, P = 0.02, and P = 0.0008, respectively). The somatostatin cell density in patients with both IBS and FDP was 86 (0-194), and in those with IBS only 110 (0-206). There was no statistically significant difference between these 2 groups of patients (P = 0.6). There was no significant difference in somatostatin immunoreactivity intensity between the controls. The diarrhea score of the Birmingham IBS symptom questionnaire was inversely correlated with somatostatin cell density (r = 0.38; P = 0.0007) and was positively correlated with that of constipation (r = 0.64; P < 0.0001).CONCLUSION: The finding of abnormal endocrine cells in the oxyntic mucosa shows that the endocrine cell disturbances in IBS are not restricted to the intestine. Furthermore, it appears that ghrelin, serotonin and somatostatin in the oxyntic mucosa of the stomach may play an important role in the changing stool habits in IBS through their effects on intestinal motility. 相似文献